LEADER 02929nam  2200457z- 450 
001 9910557222603321
005 20211118
035   $a(CKB)5400000000041718
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/73697
035   $a(oapen)doab73697
035   $a(EXLCZ)995400000000041718
100   $a20202111d2020      |y         0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aNew Therapies in the Field of Rheumatology
210   $cFrontiers Media SA$d2020
215   $a1 online resource (144 p.)
311 08$a2-88963-545-7 
330   $aIn recent years, the long term prognosis of patients with rheumatic disease has dramatically improved, due to the enormous advances in the understanding of the pathogenesis of these diseases that have led to the development of drugs targeting the molecules directly involved in the inflammatory response. The development of these biological drugs has radically changed the therapeutic approach of inflammatory rheumatic diseases, mainly in patients resistant to standard treatment. Also in the field of conventional therapy, many new data have confirmed the effectiveness of "old" drugs, such as hydroxychloroquine, methotrexate and azathioprine, demonstrating several additional beneficial properties for the treatment of Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA) or other autoimmune diseases. Moreover, immunosuppressant developed to prevent graft rejection such as mycophenolate or tacrolimus have been demonstrated to have an important role in the treatment of rheumatic patients. Beside the well defined anti-inflammatory properties of biological and synthetic anti-rheumatic drugs, a number of additional beneficial effects have been suggested, that have been hypothesized to prevent long term complications of autoimmune diseases, such as accelerated atherosclerosis, increased cardiovascular risk and osteoporosis. This Research Topic collects new information regarding safety and effectiveness of new and old drugs for the treatment of RA, SLE, or other autoimmune diseases.
606   $aPharmacology$2bicssc
606   $aScience: general issues$2bicssc
610   $aautoimmune diseases
610   $abiological therapies
610   $adisease modifing anti- rheumatic drugs
610   $arheumatoid arthritis
610   $asystemic lupus erythematosus
615  7$aPharmacology
615  7$aScience: general issues
700   $aGerosa$b Maria$4edt$01286197
702   $aBeatrice Chighizola$b Cecilia$4edt
702   $aJakobsson$b Per-Johan$4edt
702   $aGerosa$b Maria$4oth
702   $aBeatrice Chighizola$b Cecilia$4oth
702   $aJakobsson$b Per-Johan$4oth
906   $aBOOK
912   $a9910557222603321
996   $aNew Therapies in the Field of Rheumatology$93019763
997   $aUNINA